


Wissenswertes über die *HPV-Impfung*

Elmar A. Joura

Universitätsklinik für Frauenheilkunde, AKH Wien

World age-standardized incidence rates of cervical cancer




ASR, age-standardized incidence rate; Rates per 100,000 women per year.
Data sources: IARC, Globocan 2008.

Cervical Cancer Austria <45a





Figure 5: Age-specific cervical cancer incidence compared to age-specific incidence of other cancers among women 15-44 years of age in Austria




Data sources:
IARC, Globocan 2008. Age-specific data from GLOBOCAN 2008 were obtained from IARC, personal communication.
For specific estimation methodology refer to http://globocan.iarc.fr/DataSource_and_methods.asp.

1897 Ernst Wertheim



Nobelpreis für Medizin und Biologie 2008

Harald zur Hausen



Proc. Natl. Acad. Sci. USA
Vol. 80, pp. 560–563, January 1983
Medical Sciences

Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers

(molecular cloning/blot hybridization/perinatal infection/genital cancer)

LUTZ GISSMANN*, LUTZ WÖLNİK†, HANS IKENBERG*, URSULA KOLDOVSKY‡, HANS GEORG SCHNÜRCH‡, AND HARALD ZUR HAUSEN*

*Institut für Virologie, Zentrum für Hygiene, Universität Freiburg, Hermann-Herder-Strasse 11, 7800 Freiburg, Federal Republic of Germany; †Universitäts-Frauenklinik, Pilgrimstein 3, 3550 Marburg, Federal Republic of Germany; and ‡Universitäts-Frauenklinik, Mohrenstrasse, 4000 Düsseldorf, Federal Republic of Germany

Communicated by Gertrude Henle, October 13, 1982

ABSTRACT Human genital tumors as well as recurrent laryngeal papillomas were analyzed for the presence of human papillomavirus (HPV) 6 and HPV 11 sequences. HPV 11 DNA was found in 7 of 14 laryngeal papillomas; in the 7 other tumors no HPV DNA was demonstrated. HPV 11 DNA was also found in all five atypical condylomata of the cervix included in this study. Condylomata acuminata mainly contained HPV 6 DNA. From 63 biopsy specimens, 41 clearly harbored HPV 6 DNA and 13 harbored HPV 11 DNA. In three tumors accurate typing was impossible, and in six additional ones neither HPV 6 nor HPV 11 DNA could be demonstrated. The data support a genital origin of laryngeal papillomavirus infections. In 4 of 24 malignant tumors, HPV 11 DNA or related sequences were demonstrated; 2 of the 4 were biopsy specimens from invasive cancer, and the other 2 originated from carcinomata *in situ*. A possible role of this or related papillomavirus types in the induction of malignant genital tumors remains to be elucidated.

MATERIALS AND METHODS

Extraction of Cellular DNA. Biopsy materials were examined histologically and stored at -20°C or -70°C until further processing. Extraction of cellular DNA was done as described (6).

Labeling of HPV DNA. HPV 6 DNA has been cloned into pBR322 in two fragments representing approximately one-third and two-thirds of the total genome, respectively (5). HPV 11 DNA, which has been identified from a genomic library of laryngeal papilloma constructed in λ L47 (7), was subcloned in pBR322 at the single *Bam*HI site.

Both DNAs were prepared as described (10) and labeled with deoxynucleotide [α - ^{32}P]triphosphate by the nick-translation procedure to a specific activity of $>10^8$ cpm/ μg (6).

Blot Hybridization. About 10 μg of papilloma DNA was cleaved with restriction enzyme; the products were separated

FUTURE I Studie (Phase III)

- ▶ quadrivalente HPV- Impfstoff
 - ▶ größtes europäisches Studienzentrum
 - ▶ erste Probandin außerhalb der USA 6/2002
- ▶ 22. September 2006 Zulassung durch die EMEA
- ▶ **30. September 2006**
 - ▶ **I. HPV Impfung in Europa**



12.8.2013




Die HPV- Impfung wird ab Februar 2014 für alle in Österreich lebenden Kinder in der vierten Schulstufe (vollendetes neuntes Lebensjahr) kostenfrei im Rahmen des bestehenden Schulimpfprogramms angeboten

HPV- Impfung für Buben?

▶ Condylome

♂ > ♀

- ▶ Risikofaktor für die Partnerin (RR 10!)
- ▶ Herdenimmunität




HPV- assoziierte Karzinome Männer USA 2004-8

- ▶ **9400 Karzinome Oropharynx**
- ▶ **1700 Analkarzinome**
 - ▶ 2/100.000
 - ▶ 35/100.000 MSM (HIV-)
- ▶ **1000 Peniskarzinome**
 - ▶ Frauen
 - ▶ 12000 Zervixkarzinome
 - ▶ 3900 Vulva/Vaginalkarzinome
 - ▶ 3100 Analkarzinome
 - ▶ 2400 Oropharynx



HPV - Related Cancers in Men and Women



Annual new cancers and genital warts cases related to HPV 6, 11, 16 and/or 18 in Males and Females in Europe


Annual number of new cancer cases calculated based on crude incidence rates from IARC database (1998-2002) and population estimate Eurostat 2008; estimate Globocan 2008 for cervical cancer; published HPV prevalence rates were applied (for Europe, when available) Genital warts estimates based on incidence rates in UK, HPA 2007

Libby Trickett – „*I did it*“



▶ Olympic Gold Medalist - Athens 2004 - Beijing 2008 - London 2012 - WR 100m freestyle


Fig 1 Proportion of Australian born women diagnosed as having genital warts at first visit, by age group, 2004-11.



Ali H et al. BMJ 2013;346:bmj.f2032

BMJ


Fig 3 Proportion of Australian born heterosexual men diagnosed as having genital warts at first visit, by age group, 2004-11.



Ali H et al. BMJ 2013;346:bmj.f2032

Impact in Australia

Cervical high-grade abnormalities (HGA)



- ▶ A relative reduction of ~50% was observed in this age group, post vaccination vs. pre vaccination, barely 3 years after the introduction and the trend continues¹
- ▶ Similar early trends have been observed in the US on abnormal Pap smears²

1. Brotherton J et al. Lancet 2011

2. Gross et al. J Pediatr Adolesc Gynecol 2010

Rwanda





Table 1. Cumulative human papillomavirus vaccination coverage, by vaccination round, Rwanda, 2011

Coverage	Round 1	Round 2	Round 3
Girls vaccinated in school, no.	91 752	89 704	88 927
Girls vaccinated outside school, no.	2 136	3 066	3 180
Total no. of girls vaccinated	93 888	92 770	92 107
Cumulative coverage (%)	95.04	93.90	93.23

Sexuelle Übertragung

- ▶ *State Sen. George Runner of California :*
- ▶ „American money would be much better spent on other types of vaccines, since cervical cancer is a result of lifestyle choices“



The New York Times

OCTOBER 15, 2012, 12:01 AM | 99 Comments

HPV Vaccine Doesn't Alter Sexual Behavior, Study Finds

By ANAHAD O'CONNOR



Joe Raedle/Getty Images

 FACEBOOK

 TWITTER

 GOOGLE+

 SAVE

Coni Butler, an accountant in Austin, Tex., and a devout Catholic, encourages her three children to remain celibate before marriage. But that did not stop her from getting them vaccinated against human papillomavirus, or HPV, a sexually transmitted disease that raises the risk of some cancers.

Statistik Austria 2009

HPV 16/18

	Inzidenz	HPV 16/18*
CX	394	295
Vulva	128	38
Vagina	26	10
Anus	80	66
Kopf/Hals	273	68
<i>Frauen gesamt</i>	901	477
Penis	58	17
Anus	49	40
Kopf/Hals	851	212
<i>Männer gesamt</i>	958	269
Gesamt	1859	746

* Estimation

Impfplan 2014 - www.bmg.gv.at

Schulkinder

Alter→ ↓Impfung	7. Jahr	8. Jahr	9. Jahr	10. Jahr	11. Jahr	12. Jahr	13. Jahr	14. Jahr.	15. Jahr
Diphtherie (dip) Tetanus (TET) Pertussis (PEA) Poliomyelitis (IPV)	4-fach						3-fach (dip+TET+PEA) für Kinder, die vorher nur eine dip+Tet+IPV Imp- fung erhalten haben		
Hepatitis B (HBV)	Grundimmunisierung (0/1/6 Monate) oder Auffrischung								
Mumps Masern (MMR) Röteln	MMR (Nachholen bei Kindern, die keine oder nur eine Impfung erhalten haben und nicht immun sind)								
Meningokokken (MEC4)						MEC4			
Humane Papillo- maviren (HPV)			2 x HPV (0/6 Monate)			3 x HPV ¹ (ab vollendetem 12 LJ)			


Impfkalender des Gratskinderimpfprogramms für Schulkinder

- ▶ Die 1. Teilimpfung im Herbst 2014 in Schulen (4. Schulstufe)
 - ▶ Die 2. Teilimpfung 2015, 6 Monate nach der Erstimpfung im gleichen Schuljahr
 - ▶ ab 2/ 2014 an den öffentlichen Impfstellen der Bundesländer
 - ▶ kostenlos ab dem vollendeten 9. Lebensjahr bis zum vollendeten 12.
 - ▶ Catch-up Impfungen zum vergünstigten Selbstkostenpreis
 - ▶ Kinder bis zum vollendeten Lebensjahr | 5. Lebensjahr.
 - ▶ öffentlichen Impfungen in einigen Bundesländern im Auftrag der Länder im privaten Bereich
-




Immunogenität

Block SL, et al. Pediatrics 2006



qHPV GMT ratio 9-13 yo 2 dose vs 16-26 yo 3 dose



Dobson et al. JAMA 2013

Global Advisory Committee on Vaccine Safety (GAVCS)¹



- ▶ **2007:** Reviewed newly licensed qHPV vaccine safety: No safety profile concerns
- ▶ **2008:** Reviewed data related to large-scale use of qHPV vaccine and data on postlicensure surveillance.
- ▶ **2009:** Reviewed postmarketing surveillance studies and 3 reports from independent investigators.
- ▶ **2013:** With more than 175 million doses distributed worldwide, it continues to be reassured by the safety profile of the available HPV vaccines
- ▶ **2014:** GACVS has not found any safety issue that would alter any of the current recommendations for the use of the vaccine.
- ▶ No increase in risk of autoimmune diseases including MS.

^aStudies focused on syncope, hypersensitivity, anaphylaxis, and central demyelinating diseases.
qHPV=quadrivalent human papillomavirus; WHO=World Health Organization.

1. World Health Organization (WHO). *Wkly Epidemiol Rec.* 2009;84:37–40. Weekly epidemiological record Relevé épidémiologique hebdomadaire 14 FEBRUARY 2014, 89th YEAR / 14 FÉVRIER 2014, 89e ANNÉE

Conclusio

- ▶ HPV löst viele Erkrankungen aus!
- ▶ HPV Impfprogramme sind wirksam
 - ▶ Durchimpfungsrate
 - ▶ Je jünger desto effektiver
- ▶ Rascher Rückgang von Erkrankungen
- ▶ Österreich
 - ▶ Geschlechtsneutrale Impfung ✓
 - ▶ Impfalter von 9-10 ideal ✓
 - ▶ 2-Dosen nur im Kinderimpfprogramm!
- ▶ Eltern und Schulärzte sind der Schlüssel zum Erfolg!

